Compare NYT & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NYT | RDY |
|---|---|---|
| Founded | 1851 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 11.6B |
| IPO Year | 1994 | 2001 |
| Metric | NYT | RDY |
|---|---|---|
| Price | $79.12 | $13.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $72.14 | $16.90 |
| AVG Volume (30 Days) | 1.8M | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.16% | 0.52% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $1,783,639,000.00 | N/A |
| Revenue This Year | $10.58 | $7.72 |
| Revenue Next Year | $6.98 | $3.50 |
| P/E Ratio | $37.90 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.03 | $12.77 |
| 52 Week High | $87.10 | $16.17 |
| Indicator | NYT | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 52.46 |
| Support Level | $76.84 | $12.90 |
| Resistance Level | $82.49 | $13.96 |
| Average True Range (ATR) | 2.12 | 0.26 |
| MACD | -0.33 | 0.11 |
| Stochastic Oscillator | 52.76 | 61.89 |
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.